Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.13 +0.14 (+0.93%)

Streaming Delayed Price Updated: 1:48 PM EST, Jan 14, 2026 Add to My Watchlist

Price and Volume

Volume	403,861
Open	15.00
Bid (Size)	15.11 (100)
Ask (Size)	15.15 (400)
Prev. Close	14.99
Today's Range	14.76 - 15.23
52wk Range	6.550 - 16.54
Shares Outstanding	128,395,927
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗

December 02, 2025

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Via The Motley Fool

AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen ↗

November 07, 2025

Aurinia Pharmaceuticals (AUPH) exemplifies a top growth stock, showing explosive earnings growth, soaring cash flow, and consistent earnings surprises.

Via Chartmill

Performance

YTD	-1.4%	-1.4%
1 Month	-3.6%	-3.6%
3 Month	+34.7%	+34.7%
6 Month	+68.3%	+68.3%
1 Year	+94.7%	+94.7%

More News

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

November 04, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery ↗

September 29, 2025

Via Stocktwits

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

A Peek at Aurinia Pharmaceuticals's Future Earnings ↗

November 03, 2025

Via Benzinga

FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse ↗

November 03, 2025

Via Benzinga

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

November 03, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗

November 02, 2025

Via Stocktwits

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis ↗

October 17, 2025

Via Chartmill

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

October 15, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Responds to Now Retracted LinkedIn Post

September 29, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 29, 2025

Via Benzinga

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen ↗

September 26, 2025

Via Chartmill

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

Via Investor's Business Daily

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum ↗

September 05, 2025

Via Chartmill

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗

August 26, 2025

Via Investor's Business Daily

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria ↗

August 15, 2025

Via Chartmill

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗

August 04, 2025

Via Investor's Business Daily

Aurinia (AUPH) Q2 Revenue Jumps 22% ↗

July 31, 2025

Via The Motley Fool

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

July 31, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

July 24, 2025

Via Chartmill

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

July 22, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

July 01, 2025

Via Chartmill

Frequently Asked Questions

Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?

Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.

What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?

Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?

The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market

What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?

The current price of Aurinia Pharmaceuticals Inc - Common Shares is 15.13

When was Aurinia Pharmaceuticals Inc - Common Shares last traded?

The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 01/14/26 01:48 PM ET

What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?

The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 1.94B

How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?

Aurinia Pharmaceuticals Inc - Common Shares has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.